Teva replaces ADSs with NYSE ordinary shares

Teva’s ordinary shares now trade directly on the NYSE under TEVA following a 1-for-1 ADS exchange and ADS program termination.

Available on EDGAR 09/14/2026 - 04:07 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) reports that on September 14, 2026 its ordinary shares began trading on the New York Stock Exchange under the ticker “TEVA,” replacing its American depositary shares (ADSs). On the same date, Teva’s ADS program terminated, with each ADS exchanged for one ordinary share.

The company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol “TEVA.” Additional details are available via the investor relations section of Teva’s website.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Effective date of NYSE ordinary-share trading: September 14, 2026 ADS-to-ordinary-share exchange ratio: 1 ADS for 1 ordinary share NYSE trading symbol: TEVA +2 more

5 metrics

Effective date of NYSE ordinary-share trading September 14, 2026 Date when Teva’s ordinary shares began trading on the NYSE

ADS-to-ordinary-share exchange ratio 1 ADS for 1 ordinary share Each ADS was exchanged for one ordinary share upon ADS program termination

NYSE trading symbol TEVA Ticker for Teva’s ordinary shares on the New York Stock Exchange

TASE trading symbol TEVA Symbol for Teva’s ordinary shares on the Tel Aviv Stock Exchange

Principal executive office phone +1-973-658-0301 Registrant’s telephone number for Teva’s Parsippany, New Jersey office

Key Terms

American depositary shares, ADS program terminated, Tel Aviv Stock Exchange

3 terms

American depositary shares financial

"in lieu of its American depositary shares (“ADSs”), under the same ticker"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ADS program terminated financial

"Also on September 14, 2026, the Company’s ADS program terminated"

Tel Aviv Stock Exchange market

"ordinary shares continue to trade on the Tel Aviv Stock Exchange"

The Tel Aviv Stock Exchange is Israel’s main marketplace where stocks, bonds and exchange-traded funds are bought and sold, providing a centralized place for investors to trade ownership in companies and government debt. It matters because it sets real-time prices and liquidity for Israeli securities, offering a barometer of the country’s corporate health and giving investors a way to enter or exit positions much like an auction house or farmers’ market sets the price for goods.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What listing change did TEVA announce on September 14, 2026?

Teva announced that on September 14, 2026, its ordinary shares began trading on the New York Stock Exchange under the ticker TEVA, replacing its American depositary shares (ADSs).

What happened to Teva (TEVA) American depositary shares?

On September 14, 2026, Teva’s ADS program terminated, and each ADS was exchanged for one ordinary share of the company.

Does Teva (TEVA) still trade on the Tel Aviv Stock Exchange?

Yes. Teva states that its ordinary shares continue to trade on the Tel Aviv Stock Exchange under the symbol “TEVA”.

Did Teva change its ticker symbol on the NYSE?

No. Teva’s ordinary shares trade on the New York Stock Exchange under the same ticker symbol “TEVA” that its ADSs previously used.

Where can investors find more information about Teva (TEVA) share trading changes?

Teva indicates that additional information is available on the investor relations section of its website at ir.tevapharm.com.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEVA PHARMACEUTICAL INDUSTRIES LTD 00-0000000 NJ false 0000818686 0000818686 2026-09-14 2026-09-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2026

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

Israel		001-16174		Not Applicable
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

400 Interpace Parkway, #3

Parsippany New Jersey , 07054, USA

(Address of Principal Executive Offices, including Zip Code)

+1-973-658-0301

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share		TEVA		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Results of Operations and Financial Condition.

On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the ADSs previously traded, “TEVA”. Also on September 14, 2026, the Company’s ADS program terminated, with each ADS exchanged for one ordinary share. The Company’s ordinary shares continue to trade on the Tel Aviv Stock Exchange under the same symbol, “TEVA”. Additional information is available on the investor relations section of the Company’s website, available at ir.tevapharm.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: September 14, 2026				By:		/s/ Eli Kalif
						Eli Kalif
						Executive Vice President, Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB